tiprankstipranks

Adrian Rawcliffe Insider Profile

4 Followers
Adrian Rawcliffe, CEO, Director at Adaptimmune Therapeutics, holds 16.11K shares in Wave Life Sciences (Ticker: WVE), holds 44.85K shares in Adaptimmune Therapeutics (Ticker: ADAP).
tipranks
Adrian Rawcliffe

Adrian Rawcliffe
Adaptimmune Therapeutics (ADAP)
CEO, Director

Not Ranked
Adrian Rawcliffe has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$260K
88.58%
11.42%
A breakdown of Adrian Rawcliffe's holdings

Insider Roles

Wave Life Sciences
(WVE)
Director
Adaptimmune Therapeutics
(ADAP)
CEO, Director
Roles that Adrian Rawcliffe holds in companies

Most Profitable Insider Trade

Stock:
Adaptimmune Therapeutics
(ADAP)
Rating:Informative Sell
Date:Mar 22, 2018 - Mar 22, 2019
Return:+68.30%
The most profitable trade made by Adrian Rawcliffe

Adrian Rawcliffe's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Adaptimmune Therapeutics
Jan 17, 2024
CEO, Director
Uninformative Sell
27.50K
$29.64K
Wave Life Sciences
Aug 14, 2024
Director
Uninformative Buy
$229.96K
List of latest transactions for each holding click on a transaction to see Adrian Rawcliffe's performance on stock

Adrian Rawcliffe insider profile FAQ

What is the percentage of profitable transactions made by Adrian Rawcliffe?
The percentage of profitable transactions made by Adrian Rawcliffe is ―.
    What is the average return per transaction made by Adrian Rawcliffe?
    The average return per transaction made by Adrian Rawcliffe is ―.
      What stocks does Adrian Rawcliffe hold?
      Adrian Rawcliffe holds: ADAP, WVE stocks.
        What was Adrian Rawcliffe’s latest transaction?
        Adrian Rawcliffe latest transaction was an Uninformative Buy of ―.
          What was Adrian Rawcliffe's most profitable transaction?
          Adrian Rawcliffe’s most profitable transaction was an Informative Sell of ADAP stock on March 22, 2018. The return on the trade was 68.30%.
            What is Adrian Rawcliffe's role in Adaptimmune Therapeutics?
            Adrian Rawcliffe's role in Adaptimmune Therapeutics is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.